StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics
Two weeks after its stock lost more than half its value following a setback in a seven-year legal wrangle, Liquidia shares finally began bouncing back thanks to a settlement with United Therapeutics that drew mixed conclusions from four analysts about which company won out long-term. The post StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics appeared first on GEN…
Liquidia rebounded after settling a legal dispute with United Therapeutics, which had caused its stock to lose more than half its value. The settlement ended six lawsuits involving patent infringement, trade secrets, and antitrust claims between the companies. Liquidia agreed to pay $380.7 million to United Therapeutics and remove pulmonary hypertension associated with interstitial lung disease as an indication for its sole commercial product Yutrepia.
Despite the setback, analysts view the settlement as favorable for Liquidia, with Jefferies raising its price target by 22% to $55.
Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
